negative side effects of glp-1 Unraveling the safety profile receptor agonists: Mechanistic insights with a focus on semaglutide Stopping GLP-1s: Weight Regain and

MK-677 (ibutamoren) is an orally active ghrelin mimetic that induces prolonged elevations of GH and insulin-like growth factor 1 (IGF-1) by sustaining receptor activation

Clinically, GLP-1 receptor agonists act on appetite, satiety and metabolic pathways, and for many people weight will trend back toward where they started after stopping medication which is why providers and patients should plan for ongoing management, lifestyle support and monitoring

Plan your meal structure and timing

There is no universal timeline

Other studies have shown that general weight gain may increase insulin insensitivity, especially on diabetes type 1 patients